Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management

Regorafenib is a broad-spectrum oral multikinase inhibitor that targets several angiogenic, oncogenic, and stromal receptor tyrosine kinases that support the tumor microenvironment. Results from the pivotal Phase III Patients with Metastatic Colorectal Cancer Treated with Regorafenib or Placebo Afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Gazala, Moss, Rebecca A, Braiteh, Fadi, Saltzman, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949557/
https://www.ncbi.nlm.nih.gov/pubmed/24623990
http://dx.doi.org/10.2147/CMAR.S52217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949557/
https://www.ncbi.nlm.nih.gov/pubmed/24623990
http://dx.doi.org/10.2147/CMAR.S52217

Ejemplares similares